In millions, except per share items | Nov-30-21 | Nov-30-20 | Nov-30-19 | Nov-30-18 | Nov-30-17 | Nov-30-16 | Nov-30-15 | Nov-30-14 |
| 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
Revenues: |
Umbilical cord blood and cord tissue stem cell service | | | | | | | | 20.1 |
Prepacyte®-CB | | | | | | | | 1.4 |
Total revenues [+] | 28.9 | 31.1 | 31.8 | 29.2 | 25.4 | 23.1 | 21.1 | 20.1 |
Licensing | | | | | | 1.0 | 1.0 | 1.5 |
Products | | | | | | 0.4 | 0.5 | |
Services | | | | | | 21.8 | 19.6 | 18.7 |
Revenue growth | -7.3% | -2.1% | 8.9% | 15.1% | 9.8% | 9.7% | 4.8% | 6.0% |
Cost of goods sold | 9.0 | 9.7 | 10.0 | 8.5 | 6.7 | 5.8 | 5.6 | 5.6 |
Gross profit | 19.9 | 21.5 | 21.8 | 20.7 | 18.7 | 17.4 | 15.5 | 14.5 |
Gross margin | 68.9% | 69.0% | 68.5% | 70.8% | 73.5% | 75.0% | 73.3% | 72.0% |
Selling, general and administrative | 15.9 | 13.8 | 14.9 | 15.6 | 13.5 | 14.7 | 12.4 | 12.3 |
Research and development | | | 0.0 | 0.1 | 0.0 | 0.1 | 0.0 | 0.1 |
Equity in earnings | | | | | | | 0.0 | -0.4 |
Other operating expenses | 2.8 | 5.2 | 1.6 | -0.4 | | | | |
EBITDA [+] | 2.1 | 2.6 | 5.5 | 5.5 | 5.4 | 2.9 | 3.2 | 2.2 |
EBITDA growth | -20.5% | -52.7% | -0.8% | 2.6% | 87.4% | -11.8% | 48.1% | -5.6% |
EBITDA margin | 7.1% | 8.3% | 17.2% | 18.8% | 21.1% | 12.4% | 15.4% | 10.9% |
Depreciation | 0.7 | 0.1 | 0.3 | 0.2 | 0.3 | 0.4 | 0.3 | 0.5 |
EBITA | 1.3 | 2.5 | 5.2 | 5.3 | 5.0 | 2.5 | 2.9 | 1.7 |
EBITA margin | 4.5% | 8.0% | 16.2% | 18.0% | 19.9% | 10.7% | 13.9% | 8.3% |
Amortization of intangibles | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 |
EBIT [+] | 1.2 | 2.4 | 5.1 | 5.2 | 5.0 | 2.4 | 2.9 | 1.6 |
EBIT growth | -49.6% | -52.3% | -2.4% | 3.7% | 106.6% | -16.9% | 77.3% | -14.7% |
EBIT margin | 4.2% | 7.8% | 15.9% | 17.8% | 19.7% | 10.5% | 13.8% | 8.2% |
Non-recurring items [+] | | | | | | 2.0 | | 0.0 |
Asset impairment | | | | | | 2.0 | | 0.0 |
Interest expense | | | 1.7 | 1.5 | 1.3 | 0.9 | 1.3 | 1.2 |
Interest expense | 0.1 | 0.3 | 1.7 | 1.5 | 1.3 | 0.9 | 1.3 | 1.2 |
Other income (expense), net [+] | 1.5 | 2.9 | 0.0 | 0.0 | -0.1 | -2.0 | -0.7 | 0.2 |
Impairment of equity method investments | | | | | | | -0.7 | |
Asset impairment charges | | | 2.3 | | | | | |
Unrealized gain (loss) on marketable securities | 0.0 | 0.0 | 0.0 | 0.3 | | | | |
Gain (loss) on debt retirement | | | | | | 0.3 | | |
Change in value of contingent liability | | | -0.7 | -0.4 | | | | |
Other | | | 0.0 | 0.0 | -0.1 | 0.0 | 0.0 | 0.2 |
Pre-tax income | 2.6 | 5.0 | 3.4 | 3.6 | 3.6 | -2.5 | 0.9 | 0.7 |
Income taxes | 0.5 | 1.4 | 1.1 | 4.5 | 1.3 | -1.2 | -7.2 | 0.1 |
Tax rate | 20.2% | 28.1% | 32.5% | 123.6% | 36.1% | 46.7% | | 18.2% |
Net income | 2.1 | 3.6 | 2.3 | -0.9 | 2.3 | -1.3 | 8.1 | 0.6 |
Net margin | 7.2% | 11.6% | 7.2% | -2.9% | 9.1% | -5.7% | 38.4% | 2.8% |
|
Basic EPS [+] | $0.26 | $0.48 | $0.29 | ($0.11) | $0.33 | ($0.16) | $0.85 | $0.05 |
Growth | -46.7% | 63.5% | -356.6% | -134.9% | -301.3% | -119.2% | 1462.2% | 2054.4% |
Diluted EPS [+] | $0.25 | $0.45 | $0.27 | ($0.11) | $0.30 | ($0.16) | $0.83 | $0.05 |
Growth | -44.0% | 63.5% | -337.7% | -137.9% | -285.8% | -119.7% | 1458.9% | 2023.0% |
|
Shares outstanding (basic) [+] | 8.1 | 7.5 | 7.8 | 7.5 | 7.1 | 8.1 | 9.5 | 10.2 |
Growth | 7.9% | -3.2% | 4.4% | 5.7% | -12.9% | -14.9% | -6.3% | -6.3% |
Shares outstanding (diluted) [+] | 8.4 | 8.1 | 8.4 | 7.5 | 7.7 | 8.1 | 9.8 | 10.4 |
Growth | 2.7% | -3.2% | 12.7% | -2.5% | -5.7% | -17.2% | -6.1% | -5.0% |
|
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |